Ascendis Pharma AS (ASND)vsModerna Inc (MRNA)
ASND
Ascendis Pharma AS
$263.52
+0.87%
HEALTHCARE · Cap: $17.75B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 113% more annual revenue ($2.23B vs $1.05B). ASND leads profitability with a 70.9% profit margin vs -141.4%. ASND earns a higher WallStSmart Score of 61/100 (C+).
ASND
Buy61
out of 100
Grade: C+
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASND.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 53 in profit
Keeps 71 of every $100 in revenue as profit
Strong operational efficiency at 65.0%
Revenue surging 114.7% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 10.4x book value
0.0% earnings growth
Weak financial health signals
Distress zone — elevated risk
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ASND
The strongest argument for ASND centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 70.9% and operating margin at 65.0%. Revenue growth of 114.7% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ASND
The primary concerns for ASND are Price/Book, EPS Growth, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ASND profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
ASND is growing revenue faster at 114.7% — sustainability is the question.
ASND generates stronger free cash flow (283M), providing more financial flexibility.
Bottom Line
ASND scores higher overall (61/100 vs 21/100), backed by strong 70.9% margins and 114.7% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascendis Pharma AS
HEALTHCARE · BIOTECHNOLOGY · USA
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?